Oncology Research and Treatment

Published by: S. Karger AG  

People

  1. Motzer
    Motzer

Groups

  1. Department of Medicine (20)
  2. Genitourinary Oncology Service (20)
  3. Solid Tumor Oncology Division (20)
Search Within
  1. "Robert Motzer"
Formats
  1. Meeting Abstract (20)
Groups
  1. Department of Medicine (20)
  2. Genitourinary Oncology Service (20)
  3. Solid Tumor Oncology Division (20)
People
  1. Robert Motzer (20)
  2. Chung-Han Lee (1)
Years
  1. 2021 (3)
  2. 2020 (5)
  3. 2019 (2)
  4. 2018 (6)
  5. 2017 (1)
  6. 2016 (2)

More Years

Publishers
  1. S. Karger AG (20)

Results (20)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (L) plus everolimus (E) vs sunitinib (S) treatment arms
    Meeting Abstract

    Grünwald, V.; Hutson, T.; Choueiri, T. K.; Motzer, R.; Rha, S. Y.; Alyasova, A.; Merchan, J.; Gurney, H.; Peer, A.; Takagi, T.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (L) plus pembrolizumab (P) and sunitinib (S) treatment arms
    Meeting Abstract

    Grünwald, V.; Powles, T.; Kopyltsov, E.; Kozlov, V.; Alonso, G. T.; Eto, M.; Hutson, T.; Motzer, R.; Winquist, E.; Maroto, P.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial
    Meeting Abstract

    Bedke, J.; Powles, T.; Burotto, M.; Bourlon, M. T.; Hsieh, J. J.; Basso, U.; Shah, A. Y.; Suarez, C.; Porta, C.; Barrios, C.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • FRACTION-RCC: Innovative, high-throughput assessment of nivolumab plus ipilimumab (N+I) for treatment-refractory advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Loidl, W.; Choueiri, T. K.; Kluger, H.; George, S.; Tykodi, S. S.; Kuzel, T. M.; Perets, R.; Nair, S.; Procopio, G.; Carducci, M.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Long-term follow-up on overall survival and independent review of response in CheckMate 214: First-line nivolumab plus ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Grimm, M. O.; Tannir, N.; McDermott, D.; Escudier, B.; Hammers, H.; Frontera, O. A.; Plimack, E.; Barthelemy, P.; Neiman, V.; George, S.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Depth of response (DEPOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101
    Meeting Abstract

    Voss, M. H.; Motzer, R. J.; Albiges, L.; Rini, B.I.; Schmidinger, M.; Larkin, J.; Haanen, J. B. A. G.; Kollmannsberger, C.; Campbell, M. T.; Pal, S. K.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Checkmate 214 post hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma (ARCC) with sarcomatoid features (SRCC)
    Meeting Abstract

    Grimm, M. O.; McDermott, D. F.; Choueiri, T. K.; Motzer, R. J.; Frontera, O. A.; George, S.; Powles, T.; Donskov, F.; Harrison, M. R.; Rodriguez-Cid, J.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Association between depth of response (DepOR) and overall survival (OS): Exploratory analysis of nivolumab plus ipilimumab (N plus I) vs sunitinib (S) in patients with previously untreated advanced renal cell carcinoma (ARCC) in Checkmate 214
    Meeting Abstract

    Gruenwald, V.; Choueiri, T. K.; Rini, B. I.; Powles, T.; George, S.; Grimm, M. O.; McHenry, M. B.; Maurer, M.; Motzer, R. J.; Hammers, H. J.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Grüllich, C.; Rini, B. I.; Huseni, M.; Atkins, M.; McDermott, D.; Powles, T.; Escudier, B.; Banchereau, R.; Liu, L. F.; Leng, N.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • CheckMate 214 patients who discontinued first-line nivolumab + ipilimumab or sunitinib due to treatment-related adverse events
    Meeting Abstract

    Grünwald, V.; Tannir, N. M.; Motzer, R. J.; Plimack, E. R.; McDermott, D. F.; Barthélémy, P.; Porta, C.; George, S.; Powles, T.; Donskov, F.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save

    • Oncology Research and Treatment – authorized name for:

    Name ISSN / ISBN Publisher
    Oncology Research and Treatment 2296-5270 Karger
    Oncology research and treatment 22965262 Unknown
    Oncology Research and Treatment 2296-5270 S. Karger AG
    Oncology Research and Treatment 2296-5270 S. Karger AG